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Abstract
Peptide YY3-36 is a satiation hormone released postprandially into the bloodstream from L-endocrine cells in the gut
epithelia. In the current report, we demonstrate PYY3-36 is also present in murine as well as in human saliva. In mice, salivary
PYY3-36 derives from plasma and is also synthesized in the taste cells in taste buds of the tongue. Moreover, the cognate
receptor Y2R is abundantly expressed in the basal layer of the progenitor cells of the tongue epithelia and von Ebner’s
gland. The acute augmentation of salivary PYY3-36 induced stronger satiation as demonstrated in feeding behavioral studies.
The effect is mediated through the activation of the specific Y2 receptor expressed in the lingual epithelial cells. In a long-
term study involving diet-induced obese (DIO) mice, a sustained increase in PYY3-36 was achieved using viral vector-
mediated gene delivery targeting salivary glands. The chronic increase in salivary PYY3-36 resulted in a significant long-term
reduction in food intake (FI) and body weight (BW). Thus this study provides evidence for new functions of the previously
characterized gut peptide PYY3-36 suggesting a potential simple and efficient alternative therapeutic approach for the
treatment of obesity.
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Introduction
A significant portion of metabolic polypeptides has been shown
to be expressed in taste cells (TCs) or to be present in saliva. This
long list now includes insulin, leptin, adiponectin glucagon,
glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK), neuro-
peptide Y (NPY), vasoactive intestinal peptide (VIP), ghrelin, and
galanin [1,2,3,4,5,6,7,8,9,10]. In addition, the cognate receptors
for these peptide hormones are expressed in TCs or found in fibers
of afferent taste nerves in oral mucosa [4,6,7,9,10,11,12,13].
Anatomical proximity of agonists and receptors suggested their
putative roles in taste functions. Indeed, most of these polypeptides
have been implicated in modulation of different tastes such as
sweet [4,10,11,13], salty [14], sour [4,14], and umami [15]. Little,
however, is known whether these or other metabolic peptides that
are present in saliva could play a more ‘traditional’ role regulating
feeding behavior.
Peptide YY (PYY), a well-characterized molecular mediator of
satiation, is released mostly by L-endocrine cells in the distal gut
epithelia in response to the amount of calories ingested. The
anorectic action of the truncated form PYY3-36 is apparently
mediated through the inhibitory actions of its preferred Y2
receptor highly expressed in orexigenic NPY neurons in the
hypothalamic arcuate nucleus (ARC). The acute peripheral
administration of PYY3-36 resulted in significant reduction of food
intake (FI) and body weight (BW) suggesting its potential
therapeutic application for obesity treatment [16]. The latter
results, however, could not be replicated by other groups [17]
highlighting the necessity of a more detailed study of the functions
of PYY3-36 in regulating feeding behavior and satiety.
The purpose of this investigation was to identify the presence and
sources of a gut hormone PYY in saliva and to test whether salivary
PYY could be utilized to modulate feeding behavior in mice.
Results
Murine and human saliva contains satiation hormone
PYY
PYY is synthesized and secreted into the bloodstream mainly
from entero-endocrine L cells in the distal gastrointestinal tract.
Due to the rapid degradation, detection of this hormone in the
serum poses a serious technical challenge, which can be improved
by collecting samples in the presence of protease inhibitors. Using
similar technique for samples of saliva collected from mice we have
detected PYY in saliva at similar levels to those found in plasma
(45+/24.7 pg/ml and 81.4+/2 4.4 pg/ml, respectively).
Likewise, PYY3-36 was detected in saliva samples of healthy
human male volunteers that were fasted overnight (Fig. 1A).
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26137Interestingly, 30 min after consumption of a 450 kcal meal the
concentration of PYY3-36 increased significantly suggesting a
possible association between feeding and the concentration of
PYY3-36 in saliva.
To validate the RIA results, we analyzed human PYY3-36 from
saliva using mass spectrometry. To purify salivary PYY3-36,w e
utilized RP-HPLC using synthetic PYY3-36 as a positive control to
calibrate the column (Fig. 1B). After RP-HPLC of a saliva sample,
major peak (Fig. 1C) coinciding in its respective position in the
elution profile of synthetic PYY3-36 was collected and further
analyzed by MALDI-TOF. In both samples, synthetic (Fig. 1D)
and salivary PYY3-36 (Fig. 1E), identical peaks of 4052 Da, a close
experimental approximation of molecular weight for human
PYY3-36 (4050 Da), were documented. We were not able to
identify PYY1-36 in samples of human saliva using similar analysis
(data not shown).
Dual origin of salivary PYY
Some proteins enter saliva from salivary glands where they are
expressed and secreted in an exocrine fashion via zymogen
granules. Other peptides can enter saliva as a transudate from
serum. To establish the source of salivary PYY3-36 we asked
whether peptide circulating in a bloodstream can be transported
into saliva. To this end, mice were injected intraperitoneally (i.p.)
with increasing doses of murine synthetic PYY3-36 (Fig. 1F).
Indeed, there was a significant relationship between the injected
dose and the concentration of the peptide detected in saliva,
substantiating human data (Fig. 1A) and indicating that a
fraction of salivary PYY3-36 can be attributed to the circulating
peptide.
To test whether PYY3-36 is also synthesized in the oral cavity,
we have analyzed RNA isolated from murine tongue epithelia and
from circumvallate papillae (CV) of the tongue. Both sources
appear to contain PYY-specific messages with CV showing higher
levels of expression (Fig. 1G). To validate PYY expression data we
conducted immunolocalization analyses of CV. We used a-cells in
pancreatic islands in C57Bl/6J mice as a positive control (Fig. 2A)
and CV taste buds in PYY KO mice [18] as a negative control
(Fig. 2D). We observed PYY-positive cells in the taste buds on both
sides of the CV’s sulcus (Fig. 2C, F). To exclude a potential cross-
reactivity of PYY antibodies with NPY that had been previously
shown to be expressed in TCs [7], we also used NPY KO mice
[19] and detected strong PYY immunoreactivity in TCs in these
mice as well (Fig. 2B, E). The PYY appears to be localized in
secretion granules within TC cytoplasm (Fig. 2E) indicating its
functional similarity to PYY secreted from the gut entero-
endocrine L cells [20]. Collectively, these data suggest that
salivary PYY3-36 originates from two independent sources:
circulating plasma and cells in the taste buds.
Y2R is expressed in the basal epithelial cells of the
tongue
To assess a possible functional role to salivary PYY, we have
studied the expression profile of the PYY3-36-preferring receptor,
Figure. 1. Characterization of PYY3-36 origins in human and of murine saliva. (A) Concentration of PYY3-36 in human saliva during fasting
and 30 minutes after of finishing a standardized meal (n=5), *P,0.05. (B) Separation of synthetic PYY3-36 by RP-HPLC. (C) Separation of human saliva
by RP-HPLC. (D) Validation of synthetic PYY3-36 by MALDI-TOF (E) Validation of PYY3-36 from human saliva by MALDI-TOF. Arrows indicate PYY3-36
peaks. (F) PYY3-36 in saliva from male C57Bl/6J mice (n=10 per group) injected with saline or synthetic murine PYY3-36 i.p., at 10 min post injection. (G)
RT-PCR assay measuring relative PYY mRNA expression in the muscle as a (-) control, tongue epithelium, and circumvallate papillae (CV) with colon as
a( +) control in male C57Bl/6 mice (n=10 per group). (H) RT-PCR assay measuring relative Y2R mRNA expression in the tongue epithelium, muscle as a
(-) control, and brain as a (+) control in male C57Bl/6 mice (n=8 per group). *P,0.05.
doi:10.1371/journal.pone.0026137.g001
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by RT-PCR using mRNA isolated from murine tongue epithelia
(Fig. 1H). The IHC analysis was conducted using brains from
C57Bl/6J mice as a positive control [21] (Fig. 3A) and the tongue
epithelia from Y2R KO as a negative control [22] (Fig. 3B). In wt
C57Bl/6 mice, one layer of basal epithelia cells was strongly
positive for Y2R (Fig. 3C, D, E). In addition, epithelial cells lining
up ducts of the von Ebner’s gland (VEG) expressed Y2R as well
(Fig. 3C, D, F). We were unable to detect any Y2R in taste cells
(data not shown).
To establish the lineage identity of Y2R-positive cells we used
cytokeratin-5 (K5), a basal cell epithelia marker in adult [23] and
embryonic [24] salivary glands as well as a marker of progenitor
cells of the filiform papillae [25]. Staining of sequential mirror
sections with either Y2R or K5 antibodies (Fig. 4A, D, F, or
Fig. 4B, C, E, respectively) revealed that Y2R is apparently
expressed in a single apical layer of progenitor cells in the tongue
epithelium (Fig. 4A, D) as well as in von Ebner’s gland ducts and
acini (Fig. 3C, D, F, and 4F), suggesting a possible trophic role of
PYY signaling in mitotic signaling/regeneration. Coincidentally,
Figure 2. PYY is synthesized in taste cells. (A) Immunolocalization of PYY-positive cells in a-cells in the murine pancreas, a (+) control. (B)
Immunolocalization of PYY in CV of a NPY KO mouse, a control for PYY antibodies cross-reactivity. (C) Immunolocalization of PYY in CV of a C57Bl/6J
mouse (WT). (D) Immunolocalization of PYY in CV of a PYY KO mouse, a (-) control. (E) close-up of (B). (F) close-up of (C). Arrowheads point at the
apical part of a taste bud.
doi:10.1371/journal.pone.0026137.g002
Figure 3. Y2 receptor is synthesized in the epithelial cells of the tongue. (A) Immunolocalization of Y2R-positive cells in the hippocampus of
C57Bl/6J mouse (WT), a (+) control. (B) Immunolocalization of Y2R in the tongue epithelia of Y2R KO mouse, a (-) control. VEG – von Ebner’s gland. (C)
Immunolocalization of Y2R-positive cells in the CV area of the tongue of a C57Bl/6J mouse. (D) close-up of (C). (E), and (F) close ups of (D), top and
bottom rectangles, respectively.
doi:10.1371/journal.pone.0026137.g003
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innervated with neuron filaments as evident from the immuno-
staining using Neural Cell Adhesion Molecule (NCAM) neuronal
marker antibodies (Fig. 5). The anatomical location of Y2R-
positive cells, combined with their somatosensory innervation
implied a possible functional role for salivary PYY3-36 ligand and
its preferred Y2 receptor related to the regulation of feeding
behavior.
Oral PYY3-36 augmentation therapy
Intraperitoneal injection of PYY3–36 leading to higher circulat-
ing levels of the peptide results in a dose-dependent reduction in FI
Figure 4. A subpopulation of epithelial progenitor cells in the tongue epithelia expresses Y2R. Two sequential mirror sections of the
tongue were immunostained for Y2R (A, D, and and F), or Cytokeratin 5 (K5) (B, E, and C). For better viewing, K5 images were reflected horizontally.
Areas at the sulcus edge, positive for both Y2R (A) and K5 (B) (dashed rectangles), are shown as close-up images in (D) and (E), respectively. Panels (C)
and (F) show Y2R and K5-positive cells in von Ebner’s gland connecting to CV’s sulcus.
doi:10.1371/journal.pone.0026137.g004
Figure 5. Neuronal filaments innervate circumvallate papillae (CV) as well as the basal layer of cells distant from CV. Immunostaining
for NCAM in CV (A) shows subpopulation of taste cells expressing K5 (marked by arrowheads in panel D, a close-up from panel A), as well as a dense
mesh of filaments at the basolateral surfaces of the taste buds. Rectangles in (B) and (C) designate the same areas in two sequential mirror sections
stained for NCAM (red), or Y2R (green). The protrusions in the tongue epithelia surface (B, C, E, and F) are filiform papillae transversely sectioned. Even
distant from CV, the Y2R-positive epithelial layer is morphologically close to neuro-filament layer below (E). Some Y2R cells and NCAM filaments
appear to be juxtaposed (arrows in E and F).
doi:10.1371/journal.pone.0026137.g005
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mediated through changes in salivary PYY3-36, we have developed
a small spraying device that can be applied to the oral cavity in
small rodent models. After 24 hours of fasting, the PYY3-36 treated
group consumed, on average, 12.3% less food than the control
group (Fig. 6A). In separate experiments, mice were also treated
with GLP-1, or Exendin-4 peptides which were previously shown
to induce anorectic responses. Similarly, these peptides adminis-
tered by oral spray induced stronger satiation, which was also
significant for Extendin-4. Additional dose-response studies
showed that the increased doses of PYY3-36 led to a proportionate
reduction in one hour FI, down to 81% of control values at the
maximum applied dose of 12 mg/100 g (Fig. 6B). Using a similar
approach, peptide amylin was tested by oral spray application
resulting in no change of FI (data not shown).
To investigate the duration of action of orally applied PYY3-36
we conducted standard satiation studies in C57Bl/6J as well as in
PYY KO mice measuring FI over 24 hours after single treatment.
At the high treatment dose (12 mg/100 g BW) the anorexigenic
response for both C57Bl/6J and PYY
-/- was significant until the
next treatment 24 hrs later (Fig. 6C and 4D, respectively).
However, when animals were treated with the low dose (3 mg/
100 g BW), only PYY KO mice responded to the treatment in
significant manner observed after 18 and 24 hrs post experiment
(Fig. 6D).
Because of the sustained 24-hr effect, we tested whether
repeated once-a-day treatment would also affect the FI and BW
accumulation over extended period of time when animals were fed
high fat (HF) diet ad libitum. Indeed, DIO mice treated with
PYY3-36 oral spray (18 mg/100 g) consumed, on a daily basis,
significantly less HF food (Fig. 6E) resulting in retarded BW
accumulation which became significantly on day 17
th of the
treatment (Fig. 6F).
The augmentation in oral PYY3-36 had a pronounced anorectic
physiological effect similar to the previously described systemic
augmentation. To verify that PYY3-36 applied by oral spray did
not increase the circulating concentration of the peptide, we
assayed the concentration of PYY3-36 in the plasma 10 min after
oral spray (18 mg/100 g BW) treatment or after i.p. injection (6
mg/100g BW). To exclude potential interference with circulating
background PYY in the plasma, we used PYY KO mice [18].
There was no detectable PYY3-36 in the plasma in the vehicle-,
and PYY3-36-sprayed mice, while there was a significant increase
in PYY3-36 found in plasma in the i.p.- injected animals implying
that PYY3-36 applied by oral spray acted through its receptors
expressed in the oral mucosa (Fig. 6G).
Direct proof of PYY3-36/Y2R interaction was obtained by
utilizing a selective Y2 receptor antagonist BIIE0246 [26]. The
antagonist and PYY3-36 agonist (12 mg/100 g BW) were mixed at
the 50:1 molar ratio, respectively, and the mixture was used to
treat fasted mice as described above (Fig. 6H). Y2R antagonist
completely ablated the anorexigenic effect of PYY3-36 (Fig 6H).
The application of BIIE0246 alone had no effect on 2 hr FI (data
not shown).
Long-term increase in salivary PYY3-36 modulates FI and
BW
Standard satiation studies in mice as conducted and described
above, cannot be extrapolated to predict the changes in ingestive
behavior in humans due to their very different feeding patterns.
Because of their intense metabolism and high caloric requirements,
Figure 6. Oral PYY3-36 augmentation therapy. (A) Effect of PYY3-36 (3 mg/100 g BW), GLP-1(3 mg/100 g BW), or Exendin-4 (10 mg/100 g BW)
oral spray (n=10 each group) on 1 hour FI after 24 hours fasting compared to control oral spray (n=10). Experiments for each peptide were
conducted separately and the results were integrated in one graph as fractions of average amount of FI consumed by the control group. PYY3-36-, and
Exendin-4-treated mice consumed significantly less food. (B) Dose-response effect of PYY3-36 on 2 hr FI vs. control (n=8 each group). (C) Effect of
PYY3-36 oral spray on FI in C57Bl/6J mice measured at 1, 2, 6, 12, 18, and 24 hr post treatment (n=8/group). (D) Effect of PYY3-36 oral spray on FI in
PYY
-/- mice measured at 1, 2, 6, 12, 18, and 24 hr post treatment (n=8/group). (E) Average 24-hr FI in DIO mice treated with daily PYY3-36 OS (18 mg/
100 g). (F) Effect of daily PYY3-36 OS (18 mg/100 g) treatment on BW change in DIO C57Bl/6J mice (n=9 per each group). (G) Concentration of PYY3-36
in plasma of PYY KO mice 10 min after PYY3-36 (18 mg/100 g BW), or control oral spray vs. PYY3-36 injected i.p. (6 mg/100 g BW) (n=10 per group). (H)
Effect of Y2R specific antagonist BIIE0246 on anorexigenic action of PYY3-36 (n=8 per each group) measured as 2 hr FI after 24 hr fast.*P,0.05,
**P,0.01.
doi:10.1371/journal.pone.0026137.g006
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manifested in frequent meals when food provided ad lib.
Consequently, employing a sporadic acute elevation in salivary
PYY, such as obtained when using an oral spray, might not be an
optimal way to modulate feeding behavior in mice. We, therefore,
developed an alternative protocol to provide a sustained supply of
exogenous PYY3-36 in saliva using gene delivery mediated by viral
vector.Thechoice of targeted vectordelivery wasbased on previous
findings demonstrating efficient transduction of cells in the salivary
gland (SG) using recombinant adeno-associated virus (rAAV) [27].
It was anticipated that regulated secretory pathway proteins such as
PYY, when delivered as transgenes to SG, would be secreted
predominantly into saliva [28]. To this end, we constructed rAAV
encoding pre-pro-peptide YY (rAAV-PYY) (Fig. 7A).
To verify whether the transgene encoding a precursor generates
a functionally adequate PYY, we utilized the human NCI-H716
intestinal cell line [29] cultured in vitro. Cells were transduced with
rAAV-PYY and then were differentiated to display endocrine
features, in particular the formation of granule-like compartments.
In the basal state, cells transduced with rAAV-PYY secreted twice
as much PYY, but when induced with 2% meat hydrolysate (MH),
the secretion level increased by 100-fold suggesting that transgene-
encoded PYY accumulates and undergoes secretion in physiolog-
ically regulated fashion (Fig. 7B).
Next we tested the efficiency of PYY gene transfer in vivo C57Bl/
5J mice. One month after vector administration, levels of PYY had
been assayed in the blood and in saliva. While there was no
significant difference in plasma PYY levels during fasting and after
feeding after SG gene transfer (Fig. 8A), there was a 2-fold increase
in salivary PYY levels (Fig. 8B). Immunohistochemistry analysis
validated the transduction of cells in the salivary gland showing
PYY-positive cells in ductal cells (Fig. 7C), the gland cell type
previously shown transduced by rAAV2 vectors [27]. Apparently,
this modest increase in salivary PYY was sufficient to significantly
reduce weekly average calorie consumption (Fig. 8C).
Next, we asked whether a long-term increase in salivary PYY
would reduce FI and, perhaps, BW in mice rendered obese by a
high fat diet (HF, 60% calories from fat). After 120 days on a HF
diet, those mice which developed a well-pronounced obesity (with
BWs higher than 50 g) were selected. Thereafter, mice were
injected bi-laterally into SGs with either a PYY-, or GFP-encoding
rAAV. After the injection, all treated mice were fed a HF diet for 8
weeks. There was a significant difference in weekly FI between
rAAV-PYY and rAAV-GFP groups (Fig. 8D). At the end of the 8-
week study, the rAAV-PYY-treated mice had lost 24% of their BW
compared to the rAAV-GFP control group (Fig. 8E). Reduction in
BW was consistent with the weight of visceral white adipose tissue
harvested at the end of the overall experiment (Fig. 8F).
Discussion
Gut hormones play an essential role in maintaining the brain-
gut axis by inducing hunger or satiation in a short-term mode.
Recently, the expression of several of these peptides was detected
in taste cells where they have been shown to modulate taste
perception. Little, however, is known about whether these or other
gut peptides could accumulate in saliva and whether they could
play a functional role mediating satiation. In this study, we provide
evidence that the spectrum of metabolically relevant peptides
present in murine and human saliva includes gut hormone
PYY3-36 and that this peptide can be utilized to induced satiation.
Herein, we have shown that salivary PYY3-36 enters the oral
cavity at least in part from the bloodstream. It is not known
whether PYY3-36 is selectively transported from blood capillaries,
or is non-specifically leaking into the gingival crevicular fluid.
What is clear, however, is that salivary and plasma peptide
concentrations in humans increase postprandially. In addition,
because PYY is also synthesized in the TCs of the CV, it is
conceivable that PYY3-36 is secreted from these cells into saliva.
Using MS analysis, we were unable to detect PYY1-36 in human
saliva, a result that is readily explained by the action of salivary
DPP-IV secreted from salivary glands [30,31]. On the other hand,
no expression of DPP-IV had been detected in TCs inside the taste
buds [4] which opens a possibility that there are two distinct pools
of PYY: 1) PYY1-36 synthesized and contained within the taste
buds; 2) salivary PYY3-36 derived from plasma. Two PYY moieties
could play separate functions: for example, PYY1-36 in TCs
Figure 7. Validation of recombinant Adeno-associated virus encoding pre-pro-PYY (rAAV-PYY). (A) Diagram of rAAV-PYY and rAAV-GFP
cassettes: ITR - inverted terminal repeats of rAAV serotype 2; CBA - Cytomegalovirus intermediate early enhancer sequence/chicken b-acting
promoter; murine Pre-pro-Peptide YY cDNA, GFP - green fluorescence protein cDNA. (B) PYY secretion study in NCI-H716 cells. The experiment was
performed on 3 different occasions with 10 wells per group. Media was assayed at the times indicated. BS – basal secretion; MH – secretion
stimulated with 2% meat hydrolysate. (C) Cellular distribution of rAAV-PYY in salivary glands. Submandibular glands infused with rAAV-PYY removed
22 weeks after administration and evaluated for PYY expression by immunohistochemistry. The brown color indicates PYY-positive cells. Arrows
indicate PYY-positive striated ducts. (D) Positive control – PYY-stained cells in murine pancreas.
doi:10.1371/journal.pone.0026137.g007
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some taste cells [32], while PYY3-36 in saliva modulating, in part,
feeding behavior by interacting with Y2R in the tongue epithelial
cells.
Conceptually, the latter attribute of salivary PYY3-36 appears to
be redundant considering that PYY enters saliva from plasma,
while at the same time inducing satiation through hypothalamic
Y2 receptors in a well-described fashion. In the current report,
however, we have provided ample experimental evidence showing
that the augmentation of salivary PYY3-36 indeed reduced FI. The
evidence was obtained in feeding behavioral studies using 1)
escalating doses of PYY3-36, 2) GLP-1 receptor agonist (Exendin-
4), 3) selective Y2R antagonist (BIIE0246), 4) other endocrine
peptides (GLP-1, amylin), 5) re-feeding-after-fasting, and 6) ad
libitum feeding paradigms, while utilizing both C57Bl/6J and PYY
KO mice models. Moreover, we have shown that one time
treatment in mice at the beginning of a dark cycle conducted over
twenty consecutive days was sufficient to reduce the rate of BW
accumulation. This surprising persistence of the anorexigenic
effect can be explained, in part, by a nocturnal feeding pattern in
rodents, which is in contrast to the human diurnal feeding.
Rodents consume most of the food at the beginning of the dark
cycle [17] coinciding with initial effect of PYY oral spray
treatment.
To address the issue of stability of the orally applied PYY3-36 we
developed a completely different treatment paradigm, using
rAAV-mediated gene transfer. SG cells exhibit at least two distinct
secretory pathways: a predominant regulated one leading to
exocrine protein secretion into saliva via zymogen granules and a
constitutive one leading to the bloodstream [33,34]. To benefit
from this difference in secretion mechanisms, the transgene to be
used was designed to incorporate pre-pro-PYY signal sequences in
order for the transgene-encoded PYY peptide to enter the
regulated exocrine pathway. Thus, via this secretion pathway,
in-between meals the basal level of salivary PYY3-36 in treated
animals would not significantly exceed the physiological concen-
trations, hence not affecting appetite. However, upon meal onset,
the accompanying increased salivation would induce secretion of
PYY3-36 stored in SG exocrine granules while activating PYY
signaling and inducing faster satiation.
A sustained expression of pre-pro-PYY transgene from the
rAAV-transduced cells in the SG resulted in two-fold increase of
PYY3-36 in saliva with no apparent endogenous secretion into the
bloodstream. Surprisingly, this modest increase over physiological
levels resulted in significant reduction in 24 hr FI in DIO mice fed
a HF diet ad libitum. Over the course of 8 weeks vector treated mice
lost 24% their BW. In both acute and chronic experiment (Fig. 6G
and 8A), we were unable to detect any evidence of salivary PYY
diffused retrogradely to plasma in opposite direction to its
transport from plasma to saliva. Moreover, considering the
salivary milieu enriched with proteases, it is highly unlikely that
PYY3-36 would stay intact for a significant period of time, sufficient
for it to diffuse into plasma.
These data, together with Y2R selective agonist data, point to
the oral mucosal epithelial Y2R-positive cells as potential targets
for anorexigenic actions of the salivary PYY3-36 and suggests the
existence of a putative neuronal circuit initiated in the oral cavity.
We observed a juxtaposition of Y2R-positive cells and neuronal
filaments in the basal cell layer of the murine tongue. Whether this
finding observed by IHC methods is reflective of their functional
synaptic connection remains to be investigated using more precise
electron microscopy methods. However, if such a signaling
pathway exists, it might not be inducing an aversive response that
follows the peripheral administration of PYY3-36 and activation of
neurons in the circumventricular organs of the area postrema and
intermediate portion of nucleus of a solitary tract [35]. Instead, it
would activate somatosensory neurons innervating the receptor
field of the tongue epithelia converging with afferent gustatory
neuronal pathways. Experiments are in progress to characterize
this putative neural network engaged by salivary PYY3-36.
Whether the described putative circuit plays an auxiliary role to
systemic PYY signaling is a subject of an ongoing investigation.
The more parsimonious explanation, however, is that PYY3-36/
Y2R/Gi signaling in K5+ cells plays proliferative role inducing
Figure 8. Effect of PYY gene transfer to the salivary glands in C57Bl/6J mice. (A) Concentration of PYY3-36 in plasma during fasting and after
feeding. (B) Concentration of PYY3-36 in saliva. (C) Effect of PYY3-36 salivary gland gene delivery on weekly FI in mice fed HF diet. (D) Effect of PYY3-36
salivary gland gene delivery on weekly FI in DIO mice. (E) BW change in DIO C57Bl/6J treated with rAAV-GFP (control group) and rAAV-PYY over 8
weeks post injection. (F) Weight of visceral white adipose tissue at 8 weeks post injection in mice treated with rAAV (all groups were 10 animals/
group) *P,0.05.
doi:10.1371/journal.pone.0026137.g008
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mastication-related loss of keratinized lingual epithelial cells. On
the other hand, the Gi signaling in K5-progenitor cells could
mediate their motility, polarity and migration towards upper layer
of keratinized filiform papillae (Fig. 5) [36]. Regardless of the
innate physiological functions, it is clear that the augmentation of
salivary PYY3-36 can be utilized to induce satiation in a simple,
pharmacologically relevant way.
In summary, we have shown that the gut satiation peptide
PYY3-36 is present in saliva where it can play a physiological role in
food intake. The anorexigenic effect is apparently mediated
through the activation of the specific Y2 receptor expressed in the
lingual epithelial cells. We have exploited this putative metabolic
circuit to control FI, in a simple and efficient way, suggesting a
potential novel therapeutic application for the treatment of
obesity.
Methods
Mice
These studies (Approval ID #02123, ‘‘Gene Therapy for Obesity’’,
and Approval ID #03059, ‘‘Modulation of taste sensitivity by PYY
Signaling’’) were approved by the respective Institutional Animal
Care and Use Committees (IACUC) at the University of Florida
and the NIDCR (NIH). All procedures were done in accordance
with the principles of the National Research Council’s Guide for
the Care and Use of Laboratory Animals. Studies were conducted
in male mice housed at 22-24uC in a 12 hours light/dark cycle.
Mice had free access to water and food unless indicated otherwise.
NPY KO male mice [19] were purchased from Jackson Labs (129-
NPY
tm1Rpa/J), and the PYY KO colony at the UF was derived
from the respective breeders [18]. A colony of Y2R KO mice [22]
is maintained at the Garvan Institute of Medical Research.
Mouse saliva collection
Salivation was stimulated as described earlier [37]. Whole saliva
was collected for 5 min from the oral cavity into Eppendorf tubes
containing 5000 U Kallikrein inhibitor (Biomedicals) and 50 mM
DPP-IV inhibitor (Linco Research). Saliva samples were frozen at
280uC until analyzed.
Human studies
Thestudy(ApprovalID#82, ‘‘Characterizingguthormonesinsalivain
menandcorrelating them to amounts in plasma’’) had been approved by the
Institutional Review Board (IRB) of the University of Florida. IRB-
approved informed written consents were obtained from 5 lean
(BMI 19-25) males aged 18–30 with no known diseases. Participants
fasted overnight. The next morning, participants’ whole saliva
samples were collected during fasting and 30 min after eating
450 kcal meals. In each case, saliva was collected using passive
drooling approach. The collection tube contained inhibitors as
specified for mouse samples; the samples were centrifuged at 4uCt o
remove debris and frozen at 280uC until analyzed.
Plasma collection
Blood was collected from facial vein puncture into EDTA-
coated tubes (Capiject) containing protease inhibitors as described
for saliva collection. Plasma samples were frozen at 280uC until
analyzed.
Plasma and saliva hormone levels
PYY3-36 from saliva and plasma was measured by PYY3-36 RIA
kit (Phoenix Pharmaceuticals). The identification of PYY3-36 from
human saliva was performed by reverse-phase high performance
liquid chromatography (RP-HPLC) followed by Matrix-Assisted
Laser Desorption Ionization – Time of Flight (MALDI-TOF) mass
spectrometry (MS). PYY3-36 synthetic peptide (Bachem) was used
for calibration of all purification steps. Briefly, saliva was pre-
purified using a Sep-Pak C18 cartridge (Waters) followed by
purification on RP-HPLC uBondapak C18 column (Waters) as
described [38]. The PYY3-36-containing fraction was collected, air
dried and reconstituted in 0.1% formic acid in 50% acetonitrile/
water prior to analysis with MALDI-TOF as described [39,40].
Immunoflurescent localization
For specific information on the source of all antibodies,
dilutions, and controls please see Table 1.
PYY. Tissues were harvested from overnight fasted animals,
immersed in Bouin’s fixative for 8 hrs at 4uC, dehydrated,
paraffin-embedded and sectioned in a rotary microtome at 4
mM thicknesses. For PYY immunolocalization, tissues were
blocked with 3% H2O2 in methanol followed by antigen
retrieval with Trypsin (DIGEST-ALL 2, Invitrogen), blocking
with 5% natural donkey serum in TNT (0.1 M Tris-HCl, pH 7.5,
0.15 M NaCl and 0.05% Tween 20), overnight incubation with
rabbit anti-PYY in TNT, blocking with Image-iTH FX Signal
Enhancer (Invitrogen) and detection with donkey anti-rabbit Alexa
Fluor 488 in TNT (1:1000, Invitrogen).
Table 1. Antibodies used for immunolocalization studies.
Antibody Host Supplier Dilution Specificity/Control
Anti-PYY Rabbit Abcam (Cambridge, MA, USA;
cat. No. ab22663)
1:2000 Staining absent when primary or secondary antibodies omitted.
Staining visible when PYY KO tissues were used due to partial cross
reactivity with NPY (25%). Staining visualized in NPY KO tissues. Use
of this antibody has been reported previously.
Anti-Y2R Rabbit Neuromics (Edina, MN, USA;
cat. No. RA14112)
1:3000 (using
TSA Kit)
Staining absent when primary or secondary antibodies omitted, or in
NPY Y2 receptor KO. Use of this antibody has been reported
previously. Western blot analysis on hippocampal membrane
fractions revealed a single band of 44 kDa (Stanic et al, J Comp
Neurol 2011, v.519, p. 1219-1257).
Anti-NCAM Rabbit Millipore (Temecula, CA, USA;
cat. No. AB5032)
1:500 Staining absent when primary or secondary antibodies omitted.
Anti-Keratine 5 Rabbit Covance (Emerit, CA, USA;
cat. No. PRB-160P)
1:1000 Staining absent when primary or secondary antibodies omitted.
doi:10.1371/journal.pone.0026137.t001
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immediately frozen. 4 mM thick sections were cut using a
cryostat (Leica CM3050 S; Leica Microsystems, Nussloch
GmbH, Germany) and then fixed in 4% paraformaldehyde for
10 min. Y2R immunolocalization was done with the TSA kit
(Perkin Elmer). Tissues were blocked in 0.9% H2O2 in TBS for
30 min followed by blocking with TNB (0.1 M Tris-HCl, pH 7.5,
0.15 M NaCl and 0.5% Blocking Reagent from Perkin Elmer),
incubation with rabbit anti-Y2R in TBS, incubation with goat
anti-rabbit MACH 2 HRP-polymer (Biocare Medical) and
detection with Fluorescein provided in the TSA kit (1:300).
Cytokeratin-5, NCAM. The same as for Y2R detection
protocol was followed, but after incubation with primary
antibodies, sections were blocked with Image-iTH FX Signal
Enhancer (Invitrogen) and incubated with goat anti-rabbit Cy3
(1:800, Jackson Immunoresearch) for visualization. All sections
were counterstained with DAPI.
Relative quantitative RT-PCR analysis
RNA extraction, purification, cDNA synthesis and RT-PCR
amplification was done as described in Aslanadi et al [41].
Samples from each animal were treated individually through the
end of the analysis.
PYY3-36 acute augmentation studies
The concentration of PYY3-36 in the oral cavity was acutely
increased by utilizing an oral spray. One ml total volume sterile
vials were obtained from Sephora. Murine PYY3-36 (Bachem) was
diluted in sterile H2O. All 8–10 weeks old mice were individually
housed. Mice were conditioned to the oral spray with vehicle after
24 hours fast on three separate occasions. Groups were random-
ized by FI and BW. Prior to the study day, mice were fasted for
24 hours, the oral spray in a form of a single puff containing
PYY3-36 (concentration ranging from 3 to 18 mg/100 g BW, as
specified), GLP-1 (3 mg/100 g BW), Exendin-4 (10 mg/100 g
BW), or vehicle was applied without any sedation. The applied
dose was estimated using calculated average volume (,30 ml)
delivered per puff. Food was provided 10 min after the spray was
applied and the amount consumed was measured at either 1 hr
after the treatment, or at several time points (1, 2, 4, 6, 12, 18, and
24 hours). Taking into account the nocturnal feeding pattern, the
experiment was conducted during the night with the first
measurement taken at 2000 hrs. Each experiment was done at
least 3 times in a crossover manner with 8 mice per group. For the
Y2R antagonist study, BIIE0246 compound (Tocris Bioscience,
Ellisville, MO) was dissolved in 100% EtOH (0.2 mM) and the
stock solution was mixed with PYY3-36 aqueous solution at the
50:1 molar ratio (BIIE0246/PYY3-36) with the final concentration
of 2% EtOH in the mixture. Prior to this experiment, mice were
conditioned to 2% EtOH spray on three separate occasions.
Wherever practical, the behavioral experiments were conducted in
a blind fashion with the personnel uninformed about the treatment
regimen.
In vitro studies
Genetically engineered human intestinal NCI-H716 cells were
utilized to test PYY transgene as described previously by Tang and
Sambanis [29]. Briefly, cells were subjected to a differentiation
protocol and then transduced with rAAV-PYY, or rAAV-GFP
(multiplicity of infection, M.O.I. of 10
4). Forty eight hours later,
cells were washed and starved overnight in a minimal media
(DMEM, GIBCO) containing 5 mM glucose and 1% fetal bovine
serum. Cells were then washed twice with minimal media for 2 hrs
to stabilize their basal secretion followed by stimulation with 2%
meat hydrolysate (Sigma) in minimal media for one hour. For the
following 4 hrs, cells were incubated in minimal media, with
consecutive replacements of the media every hour. Harvested
media were assayed for PYY using the above-described EIA kit.
Gene transfer experiments
Long-term chronic expression of PYY3-36 was achieved by
rAAV-mediated PYY gene transfer targeted to SG. rAAV was
constructed encoding murine pre-pro-PYY cDNA driven by a
strong constitutive CMV/b-actin promoter (Fig. 7A). PYY-, and
GFP-expressing cassettes were pseudotyped into rAAV5 capsids as
having higher transduction efficiencies in murine SG [42]. The
viral vector production, purification and titering were done as
described earlier [43]. A single dose of 100 ml containing 1610
10
vector genomes was administered bilaterally into each duct of the
SG, as described previously [42].
Statistical analysis
Fixed effects ANOVA was used to determine overall model
adequacy of mouse weight as the response variable and treatment
type as the single factor in the experiment. Pairwise comparisons
of the factor were carried out using a Fisher’s Protected LSD with
a type I error rate of P#0.05. Alternatively, statistical analysis was
conducted using un-paired Student’s t-test with significance at
P,0.05.
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